Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Jul;60(1):126–131. doi: 10.1038/bjc.1989.235

A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer.

T J Powles 1, J R Hardy 1, S E Ashley 1, G M Farrington 1, D Cosgrove 1, J B Davey 1, M Dowsett 1, J A McKinna 1, A G Nash 1, H D Sinnett 1, et al.
PMCID: PMC2247327  PMID: 2679843

Abstract

Epidemiological and experimental evidence indicates that oestrogens are involved in the carcinogenic promotion of human breast cancer. We have undertaken a pilot trial of tamoxifen, an anti-oestrogen, compared to placebo given to 200 women at a high risk of developing breast cancer. The results of this trial show that acute toxicity is low and that accrual and compliance are satisfactory. Furthermore, biochemical monitoring of lipids and clotting factors indicate that tamoxifen may reduce the risk of cardiovascular deaths. At this stage no untoward long-term risks have been identified, and it is therefore proposed that a large multicentre trial should be started.

Full text

PDF
131

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradbeer J. W., Kyngdon J. Primary treatment of breast cancer in elderly women with Tamoxifen. Clin Oncol. 1983 Mar;9(1):31–34. [PubMed] [Google Scholar]
  2. Christiansen C., Christensen M. S., Transbøl I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet. 1981 Feb 28;1(8218):459–461. doi: 10.1016/s0140-6736(81)91848-1. [DOI] [PubMed] [Google Scholar]
  3. Christiansen C., Rödbro P. Long-term reproducibility of bone mineral content measurements. Scand J Clin Lab Invest. 1977 Jun;37(4):321–323. doi: 10.3109/00365517709092636. [DOI] [PubMed] [Google Scholar]
  4. Cole M. P., Jones C. T., Todd I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971 Jun;25(2):270–275. doi: 10.1038/bjc.1971.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. De Waard F., Wang D. Y. Epidemiology and prevention: workshop report. Eur J Cancer Clin Oncol. 1988 Jan;24(1):45–48. doi: 10.1016/0277-5379(88)90174-5. [DOI] [PubMed] [Google Scholar]
  6. Fentiman I. S., Powles T. J. Tamoxifen and benign breast problems. Lancet. 1987 Nov 7;2(8567):1070–1072. doi: 10.1016/s0140-6736(87)91491-7. [DOI] [PubMed] [Google Scholar]
  7. Fornander T., Rutqvist L. E., Cedermark B., Glas U., Mattsson A., Silfverswärd C., Skoog L., Somell A., Theve T., Wilking N. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989 Jan 21;1(8630):117–120. doi: 10.1016/s0140-6736(89)91141-0. [DOI] [PubMed] [Google Scholar]
  8. Gottardis M. M., Robinson S. P., Satyaswaroop P. G., Jordan V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 1988 Feb 15;48(4):812–815. [PubMed] [Google Scholar]
  9. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet. 1988 Sep 3;2(8610):563–563. doi: 10.1016/s0140-6736(88)92675-x. [DOI] [PubMed] [Google Scholar]
  10. Jordan V. C. Comparative antioestrogen action in experimental breast cancer. Adv Exp Med Biol. 1981;138:165–178. doi: 10.1007/978-1-4615-7192-6_10. [DOI] [PubMed] [Google Scholar]
  11. Jordan V. C., Fritz N. F., van Beurden M. Prophylactic tamoxifen. Lancet. 1986 Apr 19;1(8486):910–910. doi: 10.1016/s0140-6736(86)91012-3. [DOI] [PubMed] [Google Scholar]
  12. Jordan V. C. Tamoxifen and endometrial cancer. Lancet. 1988 Oct 29;2(8618):1019–1019. doi: 10.1016/s0140-6736(88)90765-9. [DOI] [PubMed] [Google Scholar]
  13. MACMAHON B., FEINLEIB M. Breast cancer in relation to nursing and menopausal history. J Natl Cancer Inst. 1960 Mar;24:733–753. doi: 10.1093/jnci/24.3.733. [DOI] [PubMed] [Google Scholar]
  14. Miller A. B., Bulbrook R. D. The epidemiology and etiology of breast cancer. N Engl J Med. 1980 Nov 20;303(21):1246–1248. doi: 10.1056/NEJM198011203032130. [DOI] [PubMed] [Google Scholar]
  15. Rose D. P., Boyar A. P., Cohen C., Strong L. E. Effect of a low-fat diet on hormone levels in women with cystic breast disease. I. Serum steroids and gonadotropins. J Natl Cancer Inst. 1987 Apr;78(4):623–626. [PubMed] [Google Scholar]
  16. Rössner S., Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis. 1984 Sep;52(3):339–346. doi: 10.1016/0021-9150(84)90064-9. [DOI] [PubMed] [Google Scholar]
  17. Sakai F., Cheix F., Clavel M., Colon J., Mayer M., Pommatau E., Saez S. Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrinol. 1978 Feb;76(2):219–226. doi: 10.1677/joe.0.0760219. [DOI] [PubMed] [Google Scholar]
  18. Tokunaga M., Norman J. E., Jr, Asano M., Tokuoka S., Ezaki H., Nishimori I., Tsuji Y. Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950-74. J Natl Cancer Inst. 1979 Jun;62(6):1347–1359. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES